From Fast Follower to Innovation Partner: The Evolution of Dealmaking between Global Biopharma and Chinese companies
For years, large pharmaceutical companies looked primarily to US biotech for external innovation, but that’s changing. China has emerged as an increasing source of novel drug development, reshaping...
